Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adrenoceptor beta 2, surface | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | conserved hypothetical protein | 0.0257 | 0.4166 | 1 |
Onchocerca volvulus | 0.054 | 1 | 0.5 | |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase, putative | 0.0257 | 0.4166 | 0.4166 |
Mycobacterium leprae | PROBABLE THYMIDYLATE SYNTHASE THYA (TS) (TSASE) | 0.054 | 1 | 0.5 |
Loa Loa (eye worm) | thymidylate synthase | 0.054 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0471 | 0.8577 | 0.8577 |
Trypanosoma brucei | dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 1 |
Echinococcus granulosus | thymidylate synthase | 0.054 | 1 | 1 |
Toxoplasma gondii | bifunctional dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 0.5 |
Mycobacterium ulcerans | thymidylate synthase | 0.054 | 1 | 0.5 |
Trypanosoma cruzi | dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 1 |
Mycobacterium tuberculosis | Probable thymidylate synthase ThyA (ts) (TSASE) | 0.054 | 1 | 1 |
Echinococcus multilocularis | cAMP and cAMP inhibited cGMP 3',5' cyclic | 0.0486 | 0.8891 | 0.8891 |
Leishmania major | dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 1 |
Echinococcus granulosus | cAMP and cAMP inhibited cGMP 3'5' cyclic | 0.0486 | 0.8891 | 0.8891 |
Brugia malayi | hypothetical protein | 0.0257 | 0.4166 | 0.4166 |
Schistosoma mansoni | bifunctional dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0431 | 0.7763 | 0.7763 |
Echinococcus multilocularis | thymidylate synthase | 0.054 | 1 | 1 |
Plasmodium vivax | bifunctional dihydrofolate reductase-thymidylate synthase, putative | 0.054 | 1 | 0.5 |
Plasmodium falciparum | bifunctional dihydrofolate reductase-thymidylate synthase | 0.054 | 1 | 0.5 |
Brugia malayi | Probable 3',5'-cyclic phosphodiesterase C32E12.2, putative | 0.0486 | 0.8891 | 0.8891 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activation (functional) | = 26 % | Agonism of human beta-3 adrenergic receptor | ChEMBL. | 9873681 |
Activation (functional) | = 26 % | Agonism of human beta-3 adrenergic receptor | ChEMBL. | 9873681 |
IC50 (binding) | = 1000 nM | Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol | ChEMBL. | 9873681 |
IC50 (binding) | = 1000 nM | Beta-2 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol | ChEMBL. | 9873681 |
IC50 (binding) | = 100000 nM | Beta-1 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol | ChEMBL. | 9873681 |
IC50 (binding) | = 100000 nM | Beta-1 adrenergic receptor binding affinity in CHO cells expressing cloned human receptor in the presence of 125 I-iodocyanopindolol | ChEMBL. | 9873681 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.